Skip to main content
Premium Trial:

Request an Annual Quote

Analysis Suggests Decreased Effectiveness

The SARS-CoV-2 vaccine from Johnson & Johnson may be less effective against the Delta and Lambda viral variants, the New York Times reports.

In a preprint posted to BioRxiv, a team of New York University researchers compared the neutralizing antibody titers elicited by the J&J, Pfizer-BioNTech, and Moderna vaccines by viral variants. They found that while the Pfizer-BioNTech and Moderna vaccines exhibited modest neutralization against the viral variants tested, the J&J vaccine showed decreased neutralization against Delta and Lambda.

"The message that we wanted to give was not that people shouldn't get the J&J vaccine, but we hope that in the future, it will be boosted with either another dose of J&J or a boost with Pfizer or Moderna," study author Nathaniel Landau from NYU tells the Times.

The Times notes that this analysis, which has yet to undergo peer review, contrasts with analyses from J&J that indicate that the vaccine is effective against the Delta variant. A J&J spokesperson adds there that the data "do not speak to the full nature of immune protection" and that their own studies showed the vaccine "generated strong, persistent activity against the rapidly spreading Delta variant."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.